Nelfinavir Non-Renewal of Marketing Authorisation in the EU
The marketing authorisation for nelfinavir (Viracept) ended on 23 January 2013 and is no longer valid in the EU.1
This was expected, as last year, manufacturers in the EU, Roche Pharmaceuticals, announced that it was not going to reapply. The original authorisation was granted in January 1998 and was subsequently renewed for additional 5-year periods in 2003 and 2008.
Despite having reduced potency compared to other protease inhibitors, nelfinavir was once widely prescribed and did not require ritonavir boosting. Although a paediatric formulation was available, the volume of powder required for reconstitution limited its use by children. However, nelfinavir was the only available protease inhibitor in many countries, until reduced price heat-stable lopinavir/ritonavir (Aluvia) was launched in 2006.
The dramatically reduced use was not helped by a manufacturing problem that resulted in product recall and a brief discontinuation of supply in 2007.2
Links to other websites are current at date of posting but not maintained.
This article was provided by HIV i-Base. It is a part of the publication HIV Treatment Bulletin. Visit HIV i-Base's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)